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Abstract: In the present study, a dense granule protein 17 (gra17) and novel putative transporter 
(npt1) double deletion mutant of Toxoplasma gondii RH strain was engineered. The protective efficacy 
of vaccination using RHΔgra17Δnpt1 tachyzoites against acute, chronic, and congenital 
toxoplasmosis was studied in a mouse model. Immunization using RHΔgra17Δnpt1 induced a 
strong humoral and cellular response, as indicated by the increased levels of anti-T. gondii specific 
IgG, interleukin 2 (IL-2), IL-10, IL-12, and interferon-gamma (IFN-γ). Vaccinated mice were 
protected against a lethal challenge dose (103 tachyzoites) of wild-type homologous (RH) strain and 
heterologous (PYS and TgC7) strains, as well as against 100 tissue cysts or oocysts of Pru strain. 
Vaccination also conferred protection against chronic infection with 10 tissue cysts or oocysts of Pru 
strain, where the numbers of brain cysts in the vaccinated mice were significantly reduced 
compared to those detected in the control (unvaccinated + infected) mice. In addition, vaccination 
protected against congenital infection with 10 T. gondii Pru oocysts (administered orally on day 5 of 
gestation) as shown by the increased litter size, survival rate and the bodyweight of pups born to 
vaccinated dams compared to those born to unvaccinated + infected dams. The brain cyst burden of 
vaccinated dams was significantly lower than that of unvaccinated dams infected with oocysts. Our 
data show that T. gondii RHΔgra17Δnpt1 mutant strain can protect mice against acute, chronic, and 
congenital toxoplasmosis by balancing inflammatory response with immunogenicity. 
Keywords: Toxoplasma gondii; immunization; dense granule protein 17; novel putative transporter 
1; live-attenuated vaccine 
 
1. Introduction 
Toxoplasma gondii, an intracellular protozoan parasite, is the etiological agent of toxoplasmosis 
that can affect nearly all warm-blooded animals and humans [1,2]. About one-third of the world’s 
population has been estimated to be chronically infected with T. gondii, and infection is generally 
asymptomatic in immunocompetent individuals [3,4]. However, T. gondii infection in 
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immunocompromised individuals, such as those with HIV/AIDS, organ transplants, or malignancies, 
can cause severe illness or even death [5]. Furthermore, primary infection with T. gondii during 
pregnancy can cause neonatal blindness, mental retardation, retinitis, and cognitive impairment [5,6]. 
Current anti-parasitic medications used to control toxoplasmosis have side effects and lack the ability 
to eliminate T. gondii tissue cysts [7]. This makes the development of new and efficacious vaccines 
against various clinical forms of toxoplasmosis a major goal for the improvement of global health. 
Vaccines are the most effective means of disease prevention and can minimize the reliance on 
and side effects of chemotherapeutics. Various strategies have been used to develop a toxoplasmosis 
vaccine, such as DNA vaccines, protein vaccines, inactivated vaccines, epitope vaccines, and live-
attenuated vaccines [8]. The only commercially available live-attenuated vaccine (Toxovax®), derived 
from S48 T. gondii tachyzoites, is used to protect against abortion in sheep [9–11]. However, this 
vaccine has limitations, such as the potential for reversion to the pathogenic phenotype [12]. Recent 
attempts to develop a toxoplasmosis vaccine have focused on developing live-attenuated T. gondii 
strains via deletion of key genes, such as RHΔgra17 and PruΔcdpk2 strains [13,14]. 
Dense granule proteins (GRAs), such as the gra17 of T. gondii, play roles in the biogenesis and 
maturation of the parasitophorous vacuole (PV) and parasitophorous vacuole membrane (PVM), and 
nutrient acquisition [15,16]. Live attenuated RHΔgra17 mutant strain can induce a protective immune 
response against T. gondii infection and reduce the parasite cyst’s burden in the brain of vaccinated 
mice and their pups [13]. In recent years, several ‘novel putative transporters’ (NPTs) were identified, 
such as the NPT protein of T. gondii (Tgnpt1), a selective transporter of arginine, which plays a crucial 
role in the growth and virulence of T. gondii [17].  
Given the important role of gra17 and npt1 in the virulence and growth of T. gondii, we 
hypothesized that genetic attenuation of T. gondii by inducing double deletion of gra17 and npt1 genes 
may produce a safer and immunogenic attenuated vaccine candidate. In this paper, we describe the 
construction and characterization of the efficacy T. gondii RHΔgra17Δnpt1 double mutant strain in the 
prevention of acute, chronic, and congenital forms of toxoplasmosis.  
2. Materials and Methods 
2.1. Mice 
Seven- to nine-week-old male and female Kunming mice were purchased from the Center of 
Laboratory Animals of Lanzhou Veterinary Research Institute (LVRI). This study was approved by 
the Animal Ethics Committee of LVRI, Chinese Academy of Agricultural Sciences. Kunming mice 
were used because of their ability to produce more pups per litter [18], providing better means to 
examine the protection induced by vaccination against congenital infection. In addition, compared to 
BALB/c and C57BL/6 mice, Kunming mice had more susceptibility to acute and chronic T. gondii 
infection [11]. 
2.2. Parasites 
Tachyzoites of T. gondii type 1 RH strain, and type ToxoDB#9 (PYS and TgC7) strains were 
maintained in vitro in monolayers of human foreskin fibroblasts (HFFs, ATCC SCRC-1041). HFFs 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM), containing 2% fetal bovine serum 
(FBS), as previously described [19]. Freshly egressed tachyzoites were harvested from heavily 
infected HFFs using 3-µm polycarbonate membranes. Cysts of T. gondii type 2 Pru strain were 
maintained in Kunming mice and obtained from brain homogenates as previously described [13,14]. 
Oocysts of type 2 Pru strain were prepared as previously described [20]. Briefly, a 10-week-old, 
specific-pathogen-free kitten was infected orally with ~100 cysts, which were obtained from brain 
homogenates of Kunming mice that had been infected with the Pru strain for one month. The cat 
feces were examined daily for the presence of oocysts, and once detected, oocysts were isolated as 
previously described [21]. To induce sporulation, the purified oocysts were suspended in 2% sulfuric 
acid and incubated on a shaker at ambient temperature for one week. Once sporulation has been 
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completed, the oocysts were washed twice with 0.85% saline and stored in 2% sulfuric acid at 4˚C 
until use. 
2.3. Engineering of RHΔgra17Δnpt1 Mutant Strains 
Mutant strains were constructed using the clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 approach. All guide RNAs and primers used in this study are listed in 
Supplementary Table S1. The npt1 targeting CRISPR plasmid was constructed by replacing the UPRT 
targeting guide RNA (gRNA) in pSAG1::CAS9-U6::sgUPRT with an npt1 targeting gRNA by site-
directed mutagenesis, as described previously [13]. The CRISPR plasmid and the Ble amplicons that 
were amplified from a pSAG1-Ble plasmid were co-transfected into RHΔgra17 strain. Subsequently, 
transfectants were selected with phleomycin (for Ble), and single-cloned by limiting the dilution in 
96-well tissue culture plates seeded with HFF monolayers. Single positive clones were identified by 
diagnostic PCRs. The positive parasite mutant strain was named RHΔgra17Δnpt1. 
2.4. Optimization of the Vaccination Dose  
To evaluate the in vivo virulence of RHΔgra17Δnpt1, serial doses (102, 103, 104, 105, 106 
tachyzoites) of RHΔgra17Δnpt1 strain or 102 tachyzoites of wildtype (WT) RH strain were 
intraperitoneally (i.p.) injected into mice. The infected mice were monitored daily for the signs of 
toxoplasmosis, and the mortality was recorded for 30 days. We also examined the ability of 
RHΔgra17, RHΔnpt1, and RHΔgra17Δnpt1 to proliferate in mice. To achieve this, each mouse was 
infected i.p. with 103 tachyzoites (five mice/strain), and five days later, the parasite burden in the 
peritoneal fluid was examined by plaque assay as described previously [22]. Briefly, mice were 
humanely sacrificed, and peritoneal cells were harvested by lavage with phosphate buffered saline 
(PBS) containing 1% FBS. The harvested peritoneal cells were mechanically disrupted using a 17-
gauge needle syringe in order to liberate intracellular parasites. Then 100 µL freshly liberated 
parasites were used to infect confluent HFF monolayers maintained in RPMI1640 medium for seven 
days. Then, T. gondii-infected HFFs were fixed and stained, and the sizes and numbers of plaques 
formed by the growing tachyzoites were determined using the plaque assay as described previously 
[22]. 
2.5. Immune Responses Induced by Immunization with RHΔgra17Δnpt1 
Mice were vaccinated i.p. with 106 tachyzoites of RHΔgra17Δnpt1 or mock-vaccinated in a total 
volume of 200 µl PBS (Supplementary Figure 1). Serum samples collected at two months after 
immunization were used to detect anti-T. gondii total IgG and subclasses of IgG (IgG1, and IgG2a) 
antibodies by enzyme-linked immunosorbent assay (ELISA), as described previously [13,14]. The 
levels of cytokines in mouse splenocyte culture supernatants were determined as previously 
described [13,14]. Briefly, two months post-immunization, mice were sacrificed and splenocyte 
cultures were prepared. Splenocyte cultures were stimulated in vitro with 10 µg/mL T. gondii soluble 
tachyzoite antigen (STAg), and splenocyte culture supernatants were collected to measure the levels 
of secreted cytokines using ELISA. The interleukin 2 (IL-2) was measured at 24 h post-incubation, IL-
10 at 72 h post-incubation, and IL-12 and interferon-gamma (IFN-γ) at 96 h post-incubation, as per 
the manufacturer’s recommendations (eBioscience® Bender MedSystems GmbH, Austria). 
2.6. Protection of Mice Against Acute and Chronic Infection 
Two months after immunization, mice were injected i.p. with 103 type 1 RH, ToxoDB#9 TgC7 or 
PYS strains in order to evaluate the protection of mice against acute T. gondii. ToxoDB#9 genotype, 
the predominant genotype in China, has a similar virulence to type 1 RH [23]. To evaluate the 
protective efficacy of RHΔgra17Δnpt1 against oral cyst and oocyst challenges, 10 or 100 of tissue cysts 
or oocysts of type 2 Pru strain were used to infect mice. The infected mice were observed daily and 
the development of clinical signs of toxoplasmosis, and survival of infected mice were recorded for 
30 days. We also investigated the ability of RHΔgra17Δnpt1 to protect against chronic infection. The 
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vaccinated mice and control mice were euthanized at 30 days after infection, and their brains were 
individually homogenized in 1 mL of PBS, and the parasite cyst’s burden in the brain was determined 
as described previously [13,14]. 
2.7. Protection Against Congenital Transmission 
Two months after immunization with 106 RHΔgra17Δnpt1 tachyzoites, two female mice were 
housed in a cage with a male mouse and examined every 12 h for the presence of vaginal plugs. The 
date of the presence of the vaginal plug was considered as day 1 of gestation. Mice were orally 
inoculated with 10 oocysts of Pru strain on day 5 of gestation. The control groups consisted of six 
unvaccinated + uninfected mice (negative control) and six unvaccinated mice orally infected with 10 
oocysts (positive control). The protective efficacy of RHΔgra17Δnpt1 strain against congenital T. 
gondii infection was determined by analyzing the litter size and survival rate of the naturally 
delivered pups at birth and at 30 days old. The bodyweight of pups at 30 days old was also examined. 
Furthermore, the parasite cyst’s burden in the infected dams and their pups was assessed in the pups 
at 30 days of age, and in their dams at 30 days after delivery. 
2.8. Statistical Analysis 
Statistical analysis for the level of the differences of antibodies, cytokines, and parasite cyst 
burdens between mouse groups were performed using two-tailed, unpaired Student t-test (for 
comparing means between two groups), and one-way ANOVA analysis (for comparing means 
between ≥ three groups). The Mantel-Cox log-rank test was used for comparing the survival curves 
of the different mouse groups. A p-value < 0.05 was considered statistically significant. 
3. Results 
3.1. Construction of RHΔgra17Δnpt1 Strain 
We previously demonstrated that live-attenuated T. gondii RH strain deficient in gra17 (Figure 
1A,C) was immunogenic in mice [13]. Interestingly, the NPT1 protein of T. gondii has been reported 
to play a key role in the growth and virulence of T. gondii, and the deletion of npt1 gene in the RH 
strain also rendered the parasite immunogenic in mice [24]. We investigated whether a double 
mutant T. gondii strain deficient in gra17 gene and npt1 gene can be more immunogenic than mutant 
strain deficient in a single gene only. To accomplish this, a stable, single, and phleomycin-resistant 
strain of RHΔgra17Δnpt1 was successfully engineered by deleting the npt1 gene in RHΔgra17 strain 
using CRISPR/Cas9-mediated non-homologous end joining (Figure 1B,D). 
 
  
Microorganisms 2020, 8, 352 5 of 13 
 
 
Figure 1. Generation of double gra17 and npt1 knock-out strains of T. gondii Type 1 RH strain using 
CRISPR/Cas9. (A) A schematic illustration of CRISPR/Cas9 system used in disrupting the gra17 gene 
by insertion of pyrimethamine-resistant DHFR (DHFR*) cassette. (B) Schematic showing deletion of 
npt1 gene by insertion of a phleomycin-resistant Ble into npt1 gene. The KO-forward and KO-reverse 
primers were used to amplify the small fragment. (C) Diagnostic PCR showing that a small fragment 
was lost due to insertion of the DHFR* cassette with short extension time in the gra17 mutant strain 
compared to the wild-type strain. (D) Diagnostic PCR showing the successful knockout of the npt1 
gene in the RHΔgra17 strain. 
3.2. Characterization and Evaluation of RHΔgra17Δnpt1 Attenuation 
We examined the impact of Δgra17Δnpt1 on the virulence of WT RH T. gondii in mice, and the 
results showed that RHΔgra17Δnpt1 completely reduced the pathogenicity of T. gondii RH strain. 
Mice infected with up to 106 RHΔgra17Δnpt1 tachyzoites survived without developing clinical signs 
of toxoplasmosis. In contrast, mice infected with the WT tachyzoites became moribund and have died 
within eight days post-infection (Figure 2). These results show that double deletion of gra17 and npt1 
genes significantly reduced the pathogenicity of the virulent T. gondii strain. To further examine the 
ability of these mutants to propagate in vivo, Kunming mice were infected with RHΔgra17, RHΔnpt1, 
or RHΔgra17Δnpt1 strains (103 tachyzoites/mouse, five mice/strain) and the parasite burden in the 
peritoneal fluid was evaluated by using the plaque assay five days after infection. Our data show that 
the ability of RHΔgra17Δnpt1 strain to grow and proliferate within HFF cells was significantly 
decreased compared to RHΔgra17 strain or RHΔnpt1 strain (Figure 3), suggesting that the dual gene 
deletion has caused significant attenuation of the parasite virulence. Furthermore, at 60 days post-
immunization, no parasite cysts were detected in the brain of mice immunized with RHΔgra17Δnpt1 
strain. 
 
Figure 2. Virulence assays of RHΔgra17Δnpt1 in Kunming mice. Serial doses (102 to 106) of 
RHΔgra17Δnpt1 or 102 of wild type RH tachyzoites were i.p. inoculated into mice, and the survival 
rates and clinical signs were recorded for 30 days. Six mice were used per group. 
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Figure 3. In vivo and in vitro growth of RHΔgra17Δnpt1. Approximately 103 tachyzoites of RHΔgra17, 
RHΔnpt1, or RHΔgra17Δnpt1 were i.p. inoculated into mice. Five days later, the parasite burden in 
the peritoneal fluid was evaluated using the in vitro plaque assay. The data represent the mean ± 
standard deviation (SD) of the relative size (A) and number (B) of the plaques generated by 
tachyzoites of each of the three tested mutant strains. Considerable attenuation of RHΔgra17Δnpt1 
was demonstrated by the significant reduction in the size and number of plaques produced by this 
double mutant strain RHΔgra17Δnpt1 compared to that produced by RHΔgra17 strain or RHΔnpt1 
strain. Statistically significant differences are indicated by *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
3.3. Immune Responses Induced by Vaccination 
In order to assess the immunogenicity of RHΔgra17Δnpt1, the levels of specific anti-T. gondii IgG 
and IgG isotypes in the sera of vaccinated mice were determined using quantitative ELISA. At 60 
days post-immunization, high levels of anti-T. gondii IgG, IgG1, and IgG2a were observed in the 
immunized mice compared with naïve, unvaccinated mice, suggesting that RHΔgra17Δnpt1 induced 
a strong humoral response (Figure 4). The cytokines produced by cultured mouse spleen cells 
stimulated by STAg were detected by ELISA. As shown in Figure 5, the levels of Th1-type cytokines 
(IFN-γ, IL-2, and IL-12) in the supernatants of STAg-stimulated splenocyte cultures of immunized 
mice were significantly higher than that of the naive mice. In addition, the level of Th2-type (IL-10) 
of immunized mice was significantly higher than that of naïve mice (Figure 5). 
 
Figure 4. Serum antibody levels in mice vaccinated with RHΔgra17Δnpt1. The levels of total IgG and 
IgG isotypes (IgG1 and IgG2a) were determined in the serum of Kunming mice vaccinated with 
RHΔgra17Δnpt1. Analysis was performed by using ELISA at 60 days post-vaccination. Results are 
expressed as mean of OD450 ± SD, and level of significance was compared to control naïve mice (***, p 
< 0.001). 
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Figure 5. The levels of cytokines detected in the supernatant of splenocyte cultures of RHΔgra17Δnpt1-
vaccinated mice. Spleen cells were harvested from vaccinated and naïve mice at 60 days post-
immunization and stimulated in vitro with 10 µg/mL STAg. Evaluation of Th1 (IL-2, IL-12 and IFN-
γ) and Th2 (IL-10) cytokines in the splenocyte culture supernatants was performed using ELISA. Data 
points are represented as means ± SD. A statistically significant difference is indicated by ***, p < 0.001. 
3.4. Protection Against Acute Infection 
Mice vaccinated with 106 RHΔgra17Δnpt1 were challenged with 103 tachyzoites of type 1 strain 
RH or ToxoDB#9 strains (TgC7 or PYS) two months post-immunization. Mice were monitored for 30 
days. High rates of survival were observed in all RHΔgra17Δnpt1-immunized mice compared to 
unvaccinated mice. All mice that received vaccination survived to 30 days post-challenge with RH, 
PYS, or TgC7 strain. All unvaccinated + infected mice succumbed to the parasite challenge and died 
within 10 days after infection (Figure 6). These results indicate that vaccination using RHΔgra17Δnpt1 
has conferred significant protection against lethal T. gondii infection with virulent homologous (RH) 
strain and heterologous (PYS and TgC7) strains. 
 
Figure 6. Survival curves of vaccinated and infected mice. At 60 days post-vaccination, mice were i.p. 
challenged with 103 T. gondii tachyzoites of RH, PYS, or TgC7 strains (6 mice/strain), and monitored 
for 30 days. Survival curves of RHΔgra17Δnpt1-vaccinated mice showed a high survival rate 
compared to naïve mice. 
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3.5. Protection against Chronic Infection 
Two months after immunization, mice were orally inoculated with cysts or oocysts of Pru strain 
in order to examine the protective efficacy of vaccination with RHΔgra17Δnpt1 against chronic 
infection. As expected, all unvaccinated mice infected with 100 cysts or oocysts succumbed to illness 
within 17 days (Figure 7A,B), whereas 75% and 62.5% of the unvaccinated mice infected with 10 cysts 
or oocysts had survived, respectively (Figure 7A,B). By contrast, all RHΔgra17Δnpt1-vaccinated mice 
survived both 10 and 100 doses of cysts and oocysts (Figure 7). Parasite cyst burden in the survived 
mice was determined one month after infection. Unvaccinated mice challenged with a low dose of 
cysts or oocysts had 3215 ± 242 (cyst-infected group) and 8991 ± 1206 (oocyst-infected group) per 
brain, which was significantly higher than RHΔgra17Δnpt1-vaccinated mice which had 275 ± 98 
cysts/brain [cyst-infected group] and 461 ± 132 cysts/brain [oocyst-infected group]. In addition, mice 
vaccinated with RHΔgra17Δnpt1 challenged with a high dose (100 cysts or oocysts) had also 
significant reduction in the parasite cyst’s burden (cyst-infected group: 619 ± 211 cysts/brain; oocyst-
infected group: 983 ± 225 cysts/brain), which was similar to RHΔgra17Δnpt1-vaccinated mice 
challenged with the lower dose. These results show that RHΔgra17Δnpt1 can protect against chronic 
toxoplasmosis regardless of the parasite’s stage used to challenge the vaccinated mice. 
 
Figure 7. Protective effect of RHΔgra17Δnpt1 vaccination against chronic T. gondii infection using 
tissue cysts or oocysts. Survival rates following challenge of RHΔgra17Δnpt1-vaccinated mice with 
(A) 10 or 100 tissue cysts, or (B) 10 or 100 oocysts of type 2 Pru strain at 60 days post-vaccination over 
30 days. All RHΔgra17Δnpt1-vaccinated mice survived regardless of the inoculation dose or the 
parasite stage (cyst or oocyst) compared to naive mice. Eight mice per group were infected with 10 
cysts or oocysts, and five mice per group were infected with 100 cysts or oocysts. 
3.6. Protection Against Congenital Infection 
Pregnant mice were orally challenged with 10 T. gondii Pru oocysts on day 5 of gestation (each 
group contained six mice). Then, the abortion rate of pregnant mice, and the litter size and 
bodyweight of the neonates were recorded daily. Two dams from the unvaccinated + oocysts-infected 
group were euthanized at 14 and 17 days after infection due to inability to eat or drink, and their 
uterus showed severe pathological lesions (Figure 8A). Abortion was observed in the other four 
dams, including one dam that was euthanized at 21 days after infection due to inability to reach food 
or water. In contrast, no abortions were detected in the dams from RHΔgra17Δnpt1 vaccinated + 
oocyst-infected group and unvaccinated + uninfected mice, and all their pups were successfully 
delivered. However, the litter size and bodyweight of neonates of unvaccinated + uninfected dams 
were significantly larger compared to those of RHΔgra17Δnpt1 vaccinated + oocyst-infected dams 
(Figure 8B,C). 
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Figure 8. Protection of RHΔgra17Δnpt1-vaccinated mice against type II Pru oocyst infection on day 5 
of gestation. Two mice from the unvaccinated + oocyst-infected group were unable to eat or drink and 
were euthanized on days 14 (Mouse 2) and 17 (Mouse 1) after infection. Significant pathologic lesions 
were observed in their uterus (A). The litter size (B) and average body weight (C) of pups born to 
unvaccinated + uninfected mice versus RHΔgra17Δnpt1-vaccinated mice + infected mice were assessed 
at 30 days after birth. Data points are represented as means ± SD. Statistically significant difference 
compared with unvaccinated + uninfected (naïve) mice: **, p < 0.01, ***, p < 0.001. 
One month after birth, pups and dams from RHΔgra17Δnpt1-vaccinated + oocyst-infected mice 
and the rest of the dams from unvaccinated + oocyst-infected mice were euthanized, and their brain 
cyst’s burden was determined. The results showed that brain cysts (227 ± 138) were detected in 77.8% 
(42/54) of the pups. Also, RHΔgra17Δnpt1-vaccinated + oocyst-infected dams (703 ± 179 cysts/brain; 
six mice) had significantly less brain cyst’s burden than unvaccinated + oocyst-infected dams (11139 
± 1197 cysts/brain; 3 mice). 
4. Discussion 
Previous studies have shown that gra17 is essential for maintaining the structural integrity of the 
PV, and mediating the trafficking of substances across the PVM, whereas npt1 is essential for the 
survival and virulence of T. gondii [16,17]. Based on these facts, we hypothesized that attenuated T. 
gondii RH strain harboring double deletions in gra17 gene and npt1 gene could elicit a safer and more 
protective immune response against T. gondii infection than the strain with a single deletion only. In 
this study, the RHΔgra17Δnpt1 strain was successfully engineered using CRISPR/Cas9 method. Our 
results showed that the deletion of the gra17 gene and the npt1 gene resulted in a significant 
attenuation of the virulence of RH strain, as revealed by the significant difference in the survival rates 
and signs of illness of mice infected with mutant strain versus the WT strain. Vaccination using an 
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infection dose up to 106 RHΔgra17Δnpt1 achieved a balance between safety and immunogenicity and 
was, therefore, used in all vaccination experiments. 
Consistent with other live-attenuated T. gondii vaccines, mice vaccinated with RHΔgra17Δnpt1 
exhibited a high level of anti-T. gondii IgG antibodies [13,14,24,25]. These specific IgG antibodies play 
an important role in protection against T. gondii infection via hindering the attachment of the parasite 
to the host cells, limiting its ability to establish infection, and activation of the classical complement 
pathway [26]. Our results showed that RHΔgra17Δnpt1-vaccinated mice developed a strong humoral 
immune response, as shown by the high level of IgG1 and IgG2a antibodies compared to 
unvaccinated mice at two months post-immunization. The patterns of cytokines in the supernatant 
of cultured spleen cells showed that Th1 cytokines (IFN-γ, IL-2, and IL-12) and Th2 cytokines (IL-10) 
in RHΔgra17Δnpt1-vaccinated mice were significantly higher than those in unvaccinated mice. 
T. gondii infection can produce IFN-γ and IL-12-dependent cell-mediated immune response in 
order to inhibit tachyzoite’s proliferation [27,28]. The correlation between high levels of Th1-type 
cytokines and strong humoral immune response, and vaccination, in addition to the known role of 
Th1 cytokines in T. gondii infection strongly suggest that Th1-type cytokines elicited by 
RHΔgra17Δnpt1 might contribute to the protection of mice against a lethal challenge with WT strains 
(type 1 RH or two ToxoDB#9 strains). Also, we detected a high level of Th2 cytokine IL-10, which is 
essential for balancing the excessive inflammatory response associated with acute T. gondii infection 
[29]. Next, we explored whether the balance of Th1 and Th2 cytokines in RHΔgra17Δnpt1-vaccinated 
mice was effective in protection against chronic T. gondii infection. As expected, the immune response 
induced by RHΔgra17Δnpt1 vaccination significantly protected mice against different doses (10 and 
100) of type II Pru cysts and oocysts. Our data clearly demonstrate the ability of RHΔgra17Δnpt1 to 
significantly reduce 91.4% of the parasite cyst burden compared to unvaccinated mice. In previous 
studies, it was demonstrated that vaccination using single-gene mutants, RHΔgra17 [13] and 
RHΔnpt1 [24] resulted in 98.8% and 98.6% reduction in the parasite cyst burden, respectively. This 
finding suggests that although deletion of both gra17 and npt1 genes has considerably attenuated the 
virulence of the parasite, this was not paralleled by improvement in the double mutant’s ability to 
limit the parasite cyst burden during latent infection. 
We also examined the protective efficacy of RHΔgra17Δnpt1 against congenital toxoplasmosis. 
We simulated T. gondii infection in the first trimester, where pregnant mice were orally infected with 
10 oocysts at day 5 of gestation. Unvaccinated + oocyst-infected pregnant mice had abortion, and 
three dams could not eat or drink, and showed severe clinical signs of toxoplasmosis, and therefore 
were euthanized. This result agrees with a previous report of abortion in infected mice during the 
first trimester [30]. By contrast, mice from RHΔgra17Δnpt1-vaccinated + oocyst-infected and 
unvaccinated + uninfected groups delivered their pups successfully. Moreover, a significantly lower 
cyst burden in the brain was observed in RHΔgra17Δnpt1-vaccinated dams compared to 
unvaccinated + oocyst-infected dams. However, the litter size and bodyweight of neonates from 
RHΔgra17Δnpt1-vaccinated + oocyst-infected mice were significantly lower than that of unvaccinated 
+ uninfected mice. 
The high levels of Th1-type cytokine responses (IFN-γ, IL-2, and IL-12) protect pregnant mice 
against T. gondii infection and limit congenital transmission. However, during pregnancy, the 
maternal immune response tends to be of the Th2 humoral type in order to sustain the progress of 
pregnancy [31]. While beneficial for the pregnancy, Th2-dominated immune response can increase 
the risk of T. gondii infection in pregnant mice. The increase of Th2-related IL-10, an antiinflammatory 
cytokine produced by many subsets of activated immune cells, is interesting because it plays a key 
role in down-regulating IFN-γ responses in T. gondii-infected mice [13]. Previous studies indicated 
that IL-10-deficient C57BL/6 mice infected with T. gondii exhibited a high level of IL-12, which 
increases the levels of IFN-γ and TNF-α, and eventually led to hepatic inflammation and necrosis 
[29]. In addition, the pregnancy outcome can be improved in C57BL/6 mice infected with T. gondii by 
treatment with recombinant IL-10 and can be deteriorated in IL-10-deficient mice compared to naïve 
mice [32]. Therefore, to ensure successful pregnancy and reduce maternal susceptibility to T. gondii, 
a balanced Th1/Th2 immune response is essential. In the present study, we showed that 
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RHΔgra17Δnpt1 vaccination induced a mixed Th1/Th2 immune response in mice and improved the 
pregnancy outcome compared to unvaccinated + infected mice. However, RHΔgra17Δnpt1 
immunization did not completely block the maternal–fetal transmission, as indicated by the lower 
litter size and mean body weight of pups born to vaccinated + infected dams compared to pups born 
to unvaccinated + uninfected mice. It is possible that RHΔgra17Δnpt1 is overattenuated and cannot 
persist longer in the host; consequently, was unable to fully protect the pups. More understanding of 
how the proinflammatory and antiinflammatory cytokines are regulated post-immunization will 
advance our understanding of how RHΔgra17Δnpt1 activates host immune responses in the 
vaccinated mice. 
5. Conclusion 
The data reported in this study show that attenuated double-deletion mutant derived from the 
virulent T. gondii type 1 RH strain is safe and immunogenic, and provides protection in mice against 
virulent T. gondii challenge. A single i.p. vaccination with 106 RHΔgra17Δnpt1 tachyzoites provided 
protection against acute infection with the homologous and heterologous T. gondii strains. Also, 
RHΔgra17Δnpt1 mutant strain generated a protective immune response that increased the survival 
rate and reduced parasite cyst burden in the brain of chronically infected mice. Mice vaccinated with 
RHΔgra17Δnpt1 showed partial protection against congenital transmission of T. gondii, where 
significantly reduced cyst burdens were detected in the brain of the vaccinated dams and their pups. 
Vaccination also improved the litter size and body weight of pups born to vaccinated dams compared 
to those born to unvaccinated infected dams. These data show that RHΔgra17Δnpt1 can be a 
promising live-attenuated vaccine candidate against toxoplasmosis. Further research to understand 
the immunological mechanisms responsible for the protection and to uncover the correlates of 
protection is warranted and will be critical for advancing the development of toxoplasmosis vaccines. 
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